A study evaluating the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)

To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, 10 mg, and 20 mg over 8 weeks of treatment

Kusajili – Clinical trials directory